Cardiff Oncology Inc Share Price Today: Live Updates & Key Insights

Cardiff Oncology Inc share price today is $1.795, up -1.1%. The stock opened at $1.82 against the previous close of $1.82, with an intraday high of $1.865 and low of $1.78.

Cardiff Oncology Inc Share Price Chart

Cardiff Oncology Inc

us-stock
To Invest in {{usstockname}}
us-stock

Cardiff Oncology Inc Share Price Performance

$1.795 -0.011(-1.1%) CRDF at 23 Mar 2026 12:33 PM Biotechnology
Lowest Today 1.78
Highest Today 1.865
Today’s Open 1.82
Prev. Close 1.82
52 Week High 4.56
52 Week Low 1.48
Day’s Range: Low 1.78 High 1.865
52-Week Range: Low 1.48 High 4.56
1 day return -
1 Week return -5.01
1 month return +15.01
3 month return -38.35
6 month return -13.04
1 year return -52.56
3 year return +13.92
5 year return -83.08
10 year return -

Cardiff Oncology Inc Institutional Holdings

BlackRock Inc 5.83

Vanguard Group Inc 5.44

LAURION CAPITAL MANAGEMENT LP 3.61

Pfizer Inc 3.53

Vanguard Total Stock Mkt Idx Inv 3.03

Blair William & Co 2.85

Geode Capital Management, LLC 2.23

iShares Russell 2000 ETF 2.21

State Street Corp 1.68

Franklin Biotechnology Discv A(acc)USD 1.12

Two Sigma Investments LLC 1.06

Vanguard Institutional Extnd Mkt Idx Tr 1.00

Fidelity Small Cap Index 0.89

F.L.Putnam Investment Management 0.87

Northern Trust Corp 0.76

The Goldman Sachs Group Inc 0.67

Franklin Biotechnology Discovery A 0.64

Two Sigma Advisers, LLC 0.53

Fidelity Extended Market Index 0.52

Bank of New York Mellon Corp 0.51

Candriam Luxembourg S.C.A. 0.50

SSgA Russell Small Cap Completeness Idx 0.47

State St Russell Sm/Mid Cp® Indx SL Cl I 0.47

Morgan Stanley - Brokerage Accounts 0.45

iShares Russell 2000 Value ETF 0.43

Vanguard Russell 2000 ETF 0.43

iShares Russell 2000 Growth ETF 0.36

GSA Capital Partners LLP 0.31

NATIONAL BANK OF CANADA /FI/ 0.31

UBS Group AG 0.30

Millennium Management LLC 0.28

Charles Schwab Investment Management Inc 0.28

iShares Micro-Cap ETF 0.24

Schwab Small Cap Index 0.23

Blackrock Extended Mkt Fund CF 0.22

NT R2000 Index Fund - NL 0.20

State St Russell Sm Cap® Indx SL Cl I 0.19

Extended Equity Market Fund K 0.19

Stt Strt SPDR® Russell2000 US SmCapETF 0.18

Fidelity Total Market Index 0.17

Cardiff Oncology Inc Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Cardiff Oncology Inc Fundamentals

Market Cap 123.06 M

PB Ratio 2.7112

PE Ratio 0.0

Enterprise Value 65.58 M

Total Assets 61.88 M

Volume 429332

Cardiff Oncology Inc Company Financials

Annual Revenue FY25:null 0.0M, FY23:460000 0.5M, FY22:386000 0.4M, FY21:359000 0.4M, FY20:365993 0.4M

Annual Profit FY25:null 0.0M, FY23:null 0.0M, FY22:386000 0.4M, FY21:359000 0.4M, FY20:365993 0.4M

Annual Net worth FY25:-45876000 -45.9M, FY23:-40801000 -40.8M, FY22:-37506000 -37.5M, FY21:-27742000 -27.7M, FY20:-19279947 -19.3M

Quarterly Revenue Q4/2025:109000 0.1M, Q3/2025:120000 0.1M, Q2/2025:121000 0.1M, Q1/2025:109000 0.1M, Q3/2024:165000 0.2M

Quarterly Profit Q4/2025:109000 0.1M, Q3/2025:120000 0.1M, Q2/2025:-11459000 -11.5M, Q1/2025:109000 0.1M, Q3/2024:165000 0.2M

Quarterly Net worth Q4/2025:-7217000 -7.2M, Q3/2025:-11258000 -11.3M, Q2/2025:-13943000 -13.9M, Q1/2025:-13434000 -13.4M, Q3/2024:-11855000 -11.9M

About Cardiff Oncology Inc & investment objective

Company Information Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Organisation Biotechnology

Employees 30

Industry Biotechnology

CEO Dr. Mani Mohindru Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

Cardiff Oncology Inc FAQs

What is the share price of Cardiff Oncology Inc today?

The current share price of Cardiff Oncology Inc is $1.795.

Can I buy Cardiff Oncology Inc shares in India?

Yes, Indian investors can buy Cardiff Oncology Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Cardiff Oncology Inc shares in India?

You can easily invest in Cardiff Oncology Inc shares from India by:

Can I buy fractional shares of Cardiff Oncology Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Cardiff Oncology Inc?

Cardiff Oncology Inc has a market cap of $123.06 M.

In which sector does Cardiff Oncology Inc belong?

Cardiff Oncology Inc operates in the Biotechnology sector.

What documents are required to invest in Cardiff Oncology Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Cardiff Oncology Inc?

The PE ratio of Cardiff Oncology Inc is N/A and the PB ratio is 2.71.